Strategies to Improve on adherence to Treatment, Appointment Keeping and Viral Suppression in HIV Care at Mpumudde, Bugembe, Budondo, and Walukuba Health Centre in Jinja District- Uganda

Download Article

DOI: 10.21522/TIJPH.2013.07.04.Art019

Authors : Balidawa John


The Uganda National HIV viral load suppression prevalence of 59.6% is below the 95% target. The study conducted in in four health facilities of Jinja district, on 437 files of adult HIV clients with; missed appointments of more than two weeks, poor adherence to treatment of < 85%, and unsuppressed viral load of > 1000 viral copies per milliliter, between January and July 2019, was aimed at determining change packages to improve HIV care in the study health facilities. Data was analyzed using Microsoft excel and the following tested changes using the Deming PDSA cycles were used; Intensified health education, and adherence counseling to all patients with poor adherence, pill counting to harmonize the pills supplied with the appointment date, follow up phone calls to patients who miss appointment, creation of a one stop centre for HIV care, and increased staffing of HIV clinic. Study results showed a 13.6% prevalence of the study HIV care poor outcomes at baseline assessment. 11.8%, 65.2%, and 46.5% of the study client files were due to poor adherence to treatment, two weeks missed appointments, and unsuppressed viral load respectively at baseline assessment and 4.7%, 25.1%, and 31.5% respectively at end line assessment. 80% of the studied clients were retention in care between baseline and end line assessments. In conclusion, there was a positive effect on the patient HIV care out comes.

Keywords: Adherence to treatment, appointment keeping, and viral suppression in HIV care.


[1].   WHO, (2013). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva Switzerland: World Health Organization; 2013. http://

[2].   MoH (2016) a. Consolidated guidelines for HIV prevention, and treatment in Uganda 2016.

[3].   Cohen MS, Chen YQ, McCauley M, et al (2011).; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493–505.

[4].   ECASA Group of Consultants LTD, (2018). Uganda AIDS Country Progress Report July 2017-June 2018.

[5].   Kolab Chhim1, Gitau Mburu2, Sovannary Tuot1, Ratana Sopha1, Vohith Khol3, Pheak Chhoun1 and Siyan (2018). Factors associated with viral nonsuppression among adolescents living with HIV in Cambodia: a crosssectional study. AIDS Research and Therapy. 15:20.

[6].   Uganda Virus Research Institute (2018). National HIV Drug Resistance Prevention, Monitoring and Surveillance Activities, National Status Report 2018.

[7].   Katharina Kranzer, Stephen D. Lawn, Leigh F. Johnson, Linda-Gail Bekker, and Robin Wood, (2014). Community viral load and CD4 count distribution among people living with HIV in a South African township: implications for treatment as prevention. Europe PMC Funders Group. J Acquir Immune Defic Syndr. 2013 August 1; 63(4): 498–505. doi:10.1097/QAI.0b013e318293ae48.

[8].   Bonner K, et al. Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr. 2013;64(1):74–8.

[9].   Nasuuna Esther, Joanita Kigozi1, Lillian Babirye, Alex Muganzi, Nelson K. Sewankambo and Damalie Nakanjako, (2018). Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. Nasuuna et al. BMC Public Health (2018) 18:1048.

[10].  Martin C., Beery M, Carmichael B, Skosana C, Pahad S, Buthelezi B, Delany-Moretlwe S, Imrie J, (2018). Reaching 90-90-90 targets amongst adolescents and young people in South Africa: A model of integrated adolescent care. 12th International Workshop on HIV Treatment, Pathogenesis, and Prevention Research in Resource-limited Settings; 29 May – 1 June 2018, Kigali, Rwanda.

[11].  Garcı´a de Olalla P, Knobel H, Carmona A, Guelar A, Lo´pezColome´s JL, Cayla` JA (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune DeficSyndr 2002; 30: 10510.

[12].  MoH (2016) b. National STD/AIDS Control Program, Viral Load Monitoring Training Facilitator’s

[13].  Chalker JC, Andualem T, Gitau LN, Ntaganira J, Obua C, Tadeg H, et al (2010). Measuring adherence to antiretroviral treatment in resource-poor settings: the feasibility of collecting routine data for key indicators. BMC Health Serv Res 2010; 10: 43.

[14].  Gusdal AK, Obua C, Andualem T, Wahlstrom R, Tomson G, Peterson S, et al (2009). Voices on adherence to ART in Ethiopia and Uganda: a matter of choice or simply not an option? AIDS Care 2009; 21: 13817.

[15].  Carly Hudelson& Lucie Cluver (2015). Factors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low- and middle-income countries: a systematic review, AIDS Care: Psychological and Socio-medical Aspects of AIDS/HIV, 27:7, 805-816, DOI: 10.1080/09540121.2015.1011073

[16].  Bharatesh D. Basti,1 Venkatesha Mahesh,2 Dattatreya D. Bant,3 and Geeta V. Bathija (2017). Factors affecting antiretroviral treatment adherence among people living with human immunodeficiency virus/acquired immunodeficiency syndrome: A prospective study. Journal of family medicine and primary care.

[17].  Oku O. Afiong, Eme T. Owoaje, Oboko O. Oku and Emmanuel Monjok (2014). Prevalence and Determinants of Adherence to Highly Active Anti-Retroviral Therapy Amongst People Living with HIV/AIDS in a Rural Setting in South-South Nigeria. African Journal of Reproductive Health March 2014; 18(1): 134

[18].  Elizabeth Horstmann, Jillian Brown, Fareesa Islam, Johanna Buck, and Bruce D. Agins, (2010). Retaining HIV-Infected Patients in Care: Where Are We? Where Do We Go from Here? Clinical Infectious Diseases 2010; 50:752–761

[19].  Park WB, Choe PG, Kim SH, Jo JH, Bang JH, Kim HB, Kim NJ, Oh M, Choe KW: One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients. J Intern Med 2007, 261(3):268–275.

[20].  Smith E. O., J. D. Curb, and R. J. Hardy, “Clinic attendance in the hypertension detection and follow-up program,” Hypertension, vol. 4, no. 5, pp. 710–715, 1982. View at Google Scholar · View at Scopus

[21].  Nemes MI, Carvalho HB, Souza MF, (2004). Antiretroviral therapy adherence in Brazil. AIDS.

[22].  Lucas GM, Chaisson RE, Moore RD, (1999). Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med; 131(2):81–87.

[23].  TenoRes Study Group (2016). Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016 May;16(5):565-575.

[24].  Sethi A, Celentano D, Gange S, Moore R, Gallant J. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37(8):1112–1118.

[25].  Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, Kaleebu P, Watera C, Aghokeng A, Mutenda N, Dzangare J, Hone S, Hang ZZ, Garcia J, Garcia Z, Marchorro P, Beteta E, Giron A, Hamers R, Inzaule S, Frenkel LM, Chung MH, de Oliveira T, Pillay D, Naidoo K, Kharsany A, Kugathasan R, Cutino T, Hunt G, Avila Rios S, Doherty M, Jordan MR, Bertagnolio S. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018 Mar;18(3):346-355.

[26].  Moore CG, Wilson-Witherspoon P, Probst JC, (2001). Time and money: effects of no-shows at a family practice residency clinic. Fam Med 2001; 33(7):522–527.

[27].  Shumba c., L. Atuhaire, R. Imakit, R. Atukunda, and P. Memiah. Missed Doses and Missed Appointments: Adherence to ART among Adult Patients in Uganda. Hindawi Publishing Corporation, ISRN AIDS, Volume 2013, Article ID 270914, 7 pages,

[28].  Bigna Jean Joel R, Jean Jacques N Noubiap, Claudia S Plottel, Charles Kouanfack1, and Sinata Koulla-Shiro, (2014). Factors associated with non-adherence to scheduled medical follow-up appointments among Cameroonian children requiring HIV care: a case-control analysis of the usual-care group in the MORE CARE trial.

[29].  Setor Kunutsor,1 John Walley,1 Elly Katabira,2 Simon Muchuro,2 Hudson Balidawa,3 Elizabeth Namagala,3 and Eric Ikoona3, (2010). Clinic Attendance for Medication Refills and Medication Adherence amongst an Antiretroviral Treatment Cohort in Uganda: A Prospective Study. Hindawi Publishing Corporation AIDS Research and Treatment Volume 2010, Article ID 872396, 8 pages doi:10.1155/2010/872396.